Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GTCB 2007 ******

2.783 Posts
Pagina: «« 1 ... 124 125 126 127 128 ... 140 »» | Laatste | Omlaag ↓
  10. [verwijderd] 3 oktober 2007 12:18

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Franco-American Alliance Targets Hemophilia Market



    By John Brosky



    BioWorld International Correspondent
    LILLE, France - At least one player in France has the muscle to swim against the tide in biotechnology financings and buy into an American firm to achieve its strategic goals - the French government.

    A state-owned company, the Laboratoire Francais du Fractionnement et des Biotechnologies SA (LFB) in October 2006 purchased a 20 percent share of GTC Biotherapeutics Inc., of Framingham, Mass., for $25 million in three installments as part of a strategic agreement for joint product development and exclusive distribution rights.

    France is now the largest shareholder in publicly traded GTC (NASDAQ:GTCB). The status of the collaboration and LFB's longer-term strategy for international development were discussed at the EuroBIO conference last week, as part of a presentation on biotech-to-biotech alliances as an alternative to the dominant biotech-to-pharma deals.

    The deal gave GTC exclusive marketing rights in the U.S. and Canada for products emerging from joint development while LFB holds exclusive marketing rights in the European Union. GTC and LFB hold co-exclusive marketing rights to the rest of the world.

    According to Marc Pennacino with LFB, each partner gave to the other exclusive licenses to relevant intellectual property and know-how for development and commercialization of products.

    The partners also agreed to share costs, investments and profits "under rules for each area and governed by principles that I can not disclose," he said.

    LFB's investment in GTC stock "is not part of the joint project but an outright stock purchase to give GTC the capital it needs to grow the company," he said.

    The first program in the collaboration is development of a transgenically produced recombinant form of human factor VII a (rhFVIIa), a clotting factor for the X-linked (male) genetic disorder that will treat Type A hemophilia and may treat Type B with potential secondary uses for trauma and uncontrolled bleeding.

    LFB has demonstrated production of FVII in transgenic rabbits, and GTC's transgenic production platform is capable of larger volumes than cell culture bioreactor facilities.

    LFB and GTC said they intend to become the low-cost producer of rhFVIIa, noting that the current product on the market, NovoSeven, from Bagsvaerd, Denmark-based Novo Nordisk A/S, is high in price yet enjoys strong market growth. Sales doubled from $400 million in 2000 to $800 million in 2005, and the estimate is for $2 billion in 2012, Pennacino said.

    Another product announced by the partners is a transgenically produced CD20 monoclonal antibody. The resulting product is expected to have a target specificity similar to Rituximab but with a relatively higher antibody dependent cell-mediated cytotoxicity.

    The CD20 antibody may be considered for clinical development as a follow-on biologic in the U.S. and a biosimilar in the EU as the appropriate legislation is enacted and regulatory guidance is established.

    LFB created a subsidiary, LFB Biotechnologies (LFB-B) in September 2006 as a legal framework, allowing it to operate outside of France and to enter into agreements, such as setting up a production facility in Brazil for plasma-derived proteins.

    LFB supplies 20 plasma-derived products, 50 percent of which have trauma applications, to 1,000 hospitals in France and 40 hospitals in the UK and Germany. LFB reported 2006 sales of €310 million (US$432.2 million) and employs 1,300 people. The state-owned laboratory reports to both the French ministries of health and the economy.

    "This strategic alliance between GTC and LFB assembles all the assets and skills for a worldwide success for transgenically derived blood factors and monoclonal antibodies, and this collaboration offers a unique opportunity to meet worldwide expanding patient needs with a technological breakthrough," said Evelyne Nguyen, director of financial affairs for LFB-B, during the Lille presentation.

    The LFB-B subsidiary has 28 employees and a research and development budget of €40 million that is being boosted to €50 million for 2008, she said. The subsidiary expects to have 200 employees.

    "The challenge to LFB is international growth," Nguyen said. "Our goal is to double the current level of sales over two years and then to reach €150 million by 2012."

    GTC develops, produces and commercializes therapeutic proteins through the production of recombinant proteins in the milk of transgenic animals.

    "Transgenic production offers potentially critical advantages in the production of recombinant proteins," Rick Finnegan, GTC vice president of commercial development, told the EuroBio audience.

    He said creating a herd and providing appropriate dairy facilities can be accomplished with substantially less cost than building a bioreactor. In addition, expanding to meet future needs can be accomplished with a higher degree of flexibility in the timing of the deployment of capital.

    GTC consistently has achieved high expression rates with recombinant proteins, he said. High protein expression levels in transgenic animals, concentrated raw materials, efficiency in purification and efficient capital spending all contribute to a highly cost-effective transgenic equation. As a result, the cost of a transgenically derived product is, in most cases, substantially lower than that of a cell culture product.

    The subsidiary LFB-B also announced at EuroBio that it has acquired 51 percent control of MAbgène, a biotech company based in Alès, France, to scale up its biomanufacturing capacity for the production of recombinant proteins and monoclonal antibodies through cell culture techniques.

    LFB-B said it will scale up the site, w
  11. [verwijderd] 3 oktober 2007 16:39

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    LFB-B said it will scale up the site, which features a pilot development unit and a clinical batch production facility, to "a truly industrial dimension and manufacture commercial batches of biomolecules." LFB-B said its long-term objective is to acquire all the capital in MAbgène.



    Published October 3, 2007


2.783 Posts
Pagina: «« 1 ... 124 125 126 127 128 ... 140 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.017
AB InBev 2 5.496
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.650
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.645
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.751
Aedifica 3 916
Aegon 3.258 322.831
AFC Ajax 538 7.088
Affimed NV 2 6.296
ageas 5.844 109.892
Agfa-Gevaert 14 2.050
Ahold 3.538 74.336
Air France - KLM 1.025 35.043
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.823
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.180
AMG 971 133.335
AMS 3 73
Amsterdam Commodities 305 6.689
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 14.998
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.776
Arcelor Mittal 2.033 320.706
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.300
Aroundtown SA 1 219
Arrowhead Research 5 9.737
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.096
ASML 1.766 107.183
ASR Nederland 21 4.485
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.667
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392

Macro & Bedrijfsagenda

  1. 24 februari

    1. Vastned Q4-cijfers
    2. PostNL Q4-cijfers
    3. Ifo ondernemersvertrouwen februari (Dld)
    4. Inflatie januari def. (eur)
    5. Chicago Fed index januari (VS)
    6. Retail Estates Q3-cijfers
    7. Vastned Belgium Q4-cijfers
    8. Zoom Video Communications Q4-cijfers (VS)
    9. Hims & Hers Health - Q4-cijfers

  2. 25 februari

    1. Ackermans & Van Haaren Q4-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda